| Date | Title | Description |
| 23.07.2026 | Ukko Announces First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment | Current approaches to peanut allergy remain burdensome and largely rely on strict avoidance, highlighting the significant unmet need for safer and more precise therapies that address the underlying immunological cause of disease,” said Uri ... |
| 23.07.2026 | Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors | The FDA’s acceptance of our NDA for varegacestat is an important milestone for Immunome and for patients living with desmoid tumors,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Immunome. “We believe varegacestat has ... |
| 23.07.2026 | Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder | NEW YORK–(BUSINESS WIRE)–Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Inves... |
| 16.06.2026 | SpliSense Secures Up to $13 Million from the Cystic Fibrosis Foundation to Advance Phase 2b Study of SPL84 for Cystic Fibrosis | Cystic Fibrosis Foundation funding follows positive SPL84 Phase 2a clinical results demonstrating clinical proof-of-concept for an inhaled antisense oligonucleotide therapy in a lung disease. Funding supports the ongoing global Phase 2b stu... |
| 14.09.2025 | SpliSense Reports Positive Results from Phase 2 Study of SPL84 in Cystic Fibrosis | Results mark first evidence of potential clinical benefit of antisense oligonucleotide therapy in a pulmonary disease Encouraging safety profile with no identified safety signals to date Improvement in lung function observed in up to 70% of... |
| 19.05.2025 | OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals | OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Phar... |
| 04.09.2024 | Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger | KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) — Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s... |
| 25.07.2024 | Nectin Therapeutics Licenses Novel Antibodies to Immunome | JERUSALEM, July 25, 2024 /PRNewswire/ — Nectin Therapeutics, Ltd., a biotechnology company developing novel immunotherapies and antibody drug conjugates (ADC) to address tumor resistance, today announced a global, exclusive license agreemen... |
| 15.07.2024 | MediWound Announces $25 Million Strategic Private Placement Financing | Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzym... |
| 04.07.2024 | Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial | MISGAV, Israel, June 24, 2024 /PRNewswire/ — Biond Biologics Ltd. (“Biond” or the “Company”), a private clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform for the intracellular delivery of bi... |
| 03.04.2024 | SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis | – Funding secured from CF Foundation and current investors for SPL84 Phase 2 study – – Two additional early-stage candidates expected to commence Phase 1-2a studies over the next 12 months – JERUSALEM, April 3, 2024 /PRNewswire/ — SpliSense... |
| 03.04.2024 | CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations | The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Fou... |
| 27.03.2024 | Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome | MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL1... |
| 12.02.2024 | MediWound Reports Positive Results In Head-to-head Comparison Of EscharEx Vs SANTYL | (RTTNews) – MediWound Ltd. (MDWD) Monday reported positive results from head-to-head comparison analyses of the company’s lead asset EscharEx for the treatment of chronic wounds to SANTYL ointment. SANTYL was approved by the FDA for debridi... |
| 06.02.2024 | Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals | AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile BOTHELL, Wash. and MONMOUTH JUNCTION, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) — Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to deve... |
| 29.10.2023 | Ayala and BioSight complete the Merger between the companies | REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. |
| 10.09.2023 | SpliSense Successfully Completed Phase 1 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis | New data published in Nucleic Acid Therapeutics demonstrate broad distribution, as well as cell and nucleus penetration of SPL84 in lungs of animal models, overcoming hyper-concentrated mucus barriers, thus leading to specific and targeted ... |
| 30.07.2023 | Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement | Upon completion of the merger, the combined company will operate under the name Ayala Pharmaceuticals, Inc., and will continue to trade on the OTCQX under Ayala’s current ticker symbol (“ADXS”). |
| 24.04.2023 | FDA Approves Gamida Cell’s Cell Therapy for Treating Blood Cancers | FDA announced on April 17, 2023 the approval of Israel-based cell therapy company Gamida Cell’s Omisirge (omidubicel-onlv), a substantially modified allogeneic cord blood-based cell therapy to quicken the recovery of neutrophils, a subset o... |
| 28.02.2023 | AION Labs Launches AI Startup for De Novo Antibody Design | - |
| 08.02.2023 | Novel Alliance Responds to Big Pharma’s Most Pressing AI/ML Needs | At AION Labs, Pfizer, AstraZeneca, Merck KgGA and Teva Pharmaceuticals have partnered with the Israel Innovation Authority, Israeli Biotech Fund, Amazon Web Services and Germany’s BioMed X Institute to create and adopt gateway AI and comput... |
| 04.02.2023 | MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market | MediWound announced that it has entered into a definitive securities purchase agreement for the sale and purchase of1,964,286 shares of the Company’s ordinary shares, par value NIS 0.07, at a purchase price of $14 per share, in a registered... |
| 16.01.2023 | Drugging the Undruggable. | There’s a revolution unfolding in cancer therapeutics as researchers learn to harness the immune system to fight even the most stubborn tumors. |
| 27.12.2022 | MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma | The data shows MW005 to be safe and well-tolerated, with patients achieving complete clinical and histological clearance of their target lesions. MW005 contains the same active pharmaceutical ingredient as in NexoBrid® and EscharEx®. |
| 01.12.2022 | IBF joins Nectin Therapeutics Series A Round | Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumor... |
| 19.10.2022 | Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement | The merger would result in a combined company that will focus predominantly on the development and commercialization of Ayala’s lead program AL102 for the treatment of desmoid tumors and Advaxis’s candidate ADXS-504 in development for prost... |
| 09.10.2022 | Gamida Cell presented new long term follow-up data and health-related quality of life scores of individuals with omidubicel | Gamida Cell (NASDAQ: GMDA), shared new data showing overall survival and disease-free survival of 63% and 56% respectively. |
| 09.10.2022 | MediWound Announces $30M Raise for Clinical Trials and Production Expansion | MediWound Ltd. (Nasdaq: MDWD), which has developed and markets a burn treatment compound that is undergoing clinical trials for the treatment of wounds, announced it has raised $30 million. The collection was at market price. Investors incl... |
| 01.10.2022 | Ayala Pharmaceuticals Announced Fast Track Designation Granted by US FDA | Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AL102 for the treatment of progressing desmoid tumors. AL102 is a potent, selective, oral gamma-sec... |
| 15.09.2022 | Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 | Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) announced updated, positive interim results from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical trial evaluating investigational new drug AL102 in desmoid tumors. AL102 is a potent, sele... |
| 06.06.2022 | Gamida Cell Completes Rolling Biologics License Application Submission to the FDA | Gamida Cell (NASDAQ: GMDA), announced positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment op... |
| 27.05.2022 | Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial | - |
| 27.05.2022 | Lonza and Israel Biotech Fund Enter A Collaboration Framework Agreement | - |
| 15.12.2021 | Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson’s Disease | - |
| 18.11.2021 | Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm | - |
| 02.11.2021 | Israeli drug developer, Vensica Therapeutics, raises $16m in an investment round led by IBF | - |
| 14.10.2021 | Merck, Pfizer, AstraZeneca and Teva join forces with Amazon & IBF in the launch of a new Israel-based AI incubator | - |
| 06.07.2021 | Advaxis and Biosight Announce Entry into Definitive Merger Agreement | The Well-Funded ($50M) Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (M... |
| 13.05.2021 | SpliSense Secures $28.5 Million in Series B Financing | Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings and the Cystic Fibrosis Foundation participated in the round. |
| 12.01.2021 | Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22 | Biond to receive $125 million upfront with more than $1 billion in potential development, regulatory, and sales milestones plus royalty payments for global rights to a novel immune checkpoint inhibitor. |
| 28.12.2020 | Israel Biotech Fund is proud to take an active role in this exciting endeavour and the creation of a new Israeli innovation lab with top line partners | - |
| 02.12.2020 | Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs | The round was led by Israel Biotech Fund with participation from new investors, The Phoenix Insurance Company and Migdal Insurance Company, two of Israel’s leading institutional investors, and Biotel, as well as existing investors including... |
| 05.08.2020 | Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia | BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, announced today that the FDA has granted Fast Track designation for BST-236 for the treatment of acute myeloid leukemia ... |
| 22.07.2020 | Biosight Announces Clinical Trial Collaboration with the European Cooperative Group | BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, announced today that it has entered into a clinical trial agreement with the European Cooperative Group. The Study is ex... |
| 02.06.2020 | Biond Bio appoints Jerome Zeldis, M.D., Ph.D., to Board of Directors | Biond Biologics appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene and a member of Israel Biotech Fund Venture Advisory Team, to its Board of Directors. |
| 19.05.2020 | Biosight Strengthens Board of Directors with Appointment of Industry Executive, Gary Gordon, M.D, Ph.D. | BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, strengthens its Board of Directors with the appointment of Dr. Gary Gordon, an industry executive and a member of Israel... |
| 12.05.2020 | Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study | Gamida Cell (NASDAQ: GMDA), announced positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment op... |
| 08.05.2020 | Ayala Pharmaceuticals Announces Pricing of Initial Public Offering | Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined pa... |
| 12.03.2020 | Biosight Raises $19M in Series C Funding led by Israel Biotech Fund | BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, announced today the raising of a $19M Series C financing. The investment was led by Israel Biotech Fund, joined by SBI J... |
| 19.02.2020 | Pharma Two B Appoints David S. Tierney, MD as CEO | Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, announced today the appointment of David S. Tierney M.D. as Chief Executive Officer, effective immediat... |
| 03.10.2019 | Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients | Ayala Pharmaceuticals announced preliminary results from its ongoing Phase 2 ACCURACY study of lead investigational new drug candidate, AL101, in patients with recurrent/metastatic adenoid cystic carcinoma (ACC) with progressing disease and... |
| 03.06.2019 | Ayala’s ex-BMS drug shows promise in triple-negative breast cancer | On the back of the positive preclinical results and the recent $30 million financing round, Ayala is ready to start a phase 2 study of AL101 in TNBC. Separately, the drug is in a phase 2 trial in adenoid cystic carcinoma, with an FDA orphan... |
| 29.05.2019 | Novartis powers Notch cancer biotech Ayala to $30M series B | Novartis has powered Ayala Pharmaceuticals to a $30 million series B round. Ayala will use the cash to fund mid-phase development of pan-Notch inhibitor AL101 in adenoid cystic carcinoma (ACC). |
| 16.05.2019 | Big Year for Israeli Tissue Agnostic Company Ayala | Ayala is looking to lead the way for the country’s burgeoning biotech sector and take its gamma secretase inhibitors all the way through to Phase III. |
| 04.02.2019 | Biond Bio announced the closing of a $17 million Series B financing | The financing and due diligence were led by Israel Biotech Fund and Harel Insurance & Finance Group, with participation of Celgene Corporation, (NASDAQ: CELG), the Japanese-Israeli fund, SBI JI Innovation Fund and existing investors. |
| 04.02.2019 | Ayala entered a license agreement with Novartis | Ayala entered into an option to license agreement with Novartis for its investigational agent AL102 in multiple myeloma. |
| 18.12.2017 | Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance | Israel Biotech Fund identified the opportunity, led the due diligence and syndicated with aMoon and Harel Insurance in 2017 to form Ayala. Read the full Article |
| 19.06.2017 | Gamida Cell $40MM Financing to support its Phase 3 Trial | Israel Biotech Fund participated in Gamida Cell’s $40MM financing round which shall support the ongoing Phase 3 trial of the its FDA Breakthrough Designated clinical-stage product, NiCord, to facilitate bone marrow transplantation. Read the... |
| 03.04.2017 | Israel Biotech Fund Co-Founder and General Partner Recognized for Contribution to Liquid Biopsy Innovation | American Association for Cancer Research (AACR) Bestows 2017 Team Science Award to a Renowned Team of Investigators who Pioneered the Science of Liquid Biopsy: Luis A. Diaz, Nishant Agrawazl, Chetan Bettegowda, Frank Diehl, Peter Gibbs, Sta... |
| 27.02.2017 | Israel Biotech Fund invests in Pharma Two B | A $30MM funding round in Pharma Two B was led by Israel Biotech Fund, which syndicated the investment with leading US and Israeli investors. Read the full Article |
| 03.06.2016 | Israel Biotech Fund begins investing | Israel Biotech Fund, founded to make investments in the Israeli biotech industry, today selected cancer drug developer Vidac for its first investment.Read the full Article |
| 19.11.2015 | Biogen invests in a newly formed Israeli fund | Biogen invests in a newly formed fund dedicated to investment in Israeli and Israeli related biotech companies.Read the full Article |
